Literature DB >> 21308490

Heart fatty acid-binding protein may not be an early biomarker for anthracycline-induced cardiotoxicity in rabbits.

Ren-chun Lai1, Xu-dong Wang, Xu Zhang, Wen-qian Lin, Tie-hua Rong.   

Abstract

The objective of this study was to investigate the feasibility of using serum heart fatty acid-binding protein (H-FABP) concentrations as an early biomarker for doxorubicin-induced myocardial damage. Forty-four male rabbits were randomly divided into a control (8 rabbits) or one of four doxorubicin groups (8 rabbits in each group). Rabbits in the control group received saline, whereas rabbits in the doxorubicin group received 2 mg/kg doxorubicin weekly for 1-8 weeks. Rabbits in the doxorubicin groups received doxorubicin 2 mg/kg for one (Group 1, 8 rabbits), two (Group 2, 8 rabbits), four (Group 3, 9 rabbits), or eight (Group 4, 11 rabbits) weeks. Echocardiography was performed to measure left ventricular ejection fraction (LVEF), shortening fraction (FS), and E/A ratio. Cardiotoxicity scores were assessed by light microscopy using Billingham's method and also by electron microscopy. Serum H-FABP concentrations were quantified by a rabbit-specific enzyme-linked immunosorbent assay. Decreased LVEF, FS, and E/A ratio were detected in Group 4 (P < 0.05). Billingham cardiomyopathy scores of the rabbits in Group 3 were significantly higher (P < 0.05) than those of rabbits in the control group or Groups 1 or 2. Billingham cardiomyopathy scores in Group 4 were the highest of all groups (P < 0.05). Myocardial injury was demonstrable by electron microscopy in rabbits in Groups 2, 3, and 4. Compared with the control group, serum H-FABP concentrations increased only in Group 4 (P < 0.05). Serum H-FABP concentrations may not be a sensitive method for assessing early cardiotoxicity of doxorubicin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21308490     DOI: 10.1007/s12032-011-9843-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  17 in total

Review 1.  Long-term effects of treatments for childhood cancers.

Authors:  Jorge A Alvarez; Rebecca E Scully; Tracie L Miller; F Daniel Armstrong; Louis S Constine; Debra L Friedman; Steven E Lipshultz
Journal:  Curr Opin Pediatr       Date:  2007-02       Impact factor: 2.856

2.  Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group.

Authors:  L J Steinherz; T Graham; R Hurwitz; H M Sondheimer; R G Schwartz; E M Shaffer; G Sandor; L Benson; R Williams
Journal:  Pediatrics       Date:  1992-05       Impact factor: 7.124

3.  Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes.

Authors:  Michelle O'Donoghue; James A de Lemos; David A Morrow; Sabina A Murphy; Jacqueline L Buros; Christopher P Cannon; Marc S Sabatine
Journal:  Circulation       Date:  2006-07-31       Impact factor: 29.690

4.  Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury.

Authors:  Kathleen Gabrielson; Djahida Bedja; Scott Pin; Allison Tsao; Lucio Gama; Bibo Yuan; Nicole Muratore
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

Review 5.  Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications.

Authors:  Hassan M E Azzazy; Maurice M A L Pelsers; Robert H Christenson
Journal:  Clin Chem       Date:  2005-11-03       Impact factor: 8.327

6.  The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia.

Authors:  J M Horacek; M Vasatova; M Tichy; R Pudil; L Jebavy; J Maly
Journal:  Exp Oncol       Date:  2010-07

7.  Clinical and pathologic features of chronic adriamycin toxicosis in rabbits.

Authors:  J F Van Vleet; V J Ferrans
Journal:  Am J Vet Res       Date:  1980-09       Impact factor: 1.156

8.  Anthracycline cardiomyopathy monitored by morphologic changes.

Authors:  M E Billingham; J W Mason; M R Bristow; J R Daniels
Journal:  Cancer Treat Rep       Date:  1978-06

9.  Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.

Authors:  D Lebrecht; A Geist; U-P Ketelsen; J Haberstroh; B Setzer; U A Walker
Journal:  Br J Pharmacol       Date:  2007-05-21       Impact factor: 8.739

10.  Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction.

Authors:  Georg Haltern; Sigune Peiniger; Alexander Bufe; Gebhard Reiss; Hartmut Gülker; Thomas Scheffold
Journal:  Am J Cardiol       Date:  2009-11-13       Impact factor: 2.778

View more
  1 in total

1.  Oxidative stress markers may not be early markers of doxorubicin-induced cardiotoxicity in rabbits.

Authors:  Renchun Lai; Yuhui Long; Qiuli Li; Xu Zhang4; Tiehua Rong4
Journal:  Exp Ther Med       Date:  2011-06-30       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.